• #LGM Pharma is a Latanoprost CAS# 130209-82-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 130209-82-4
  • AHFC code: 53:32.0
  • Synonyms: Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate, Latanoprost, PhXA 41, PHXA41, UNII-6Z5B6HVF6O, XA 41, XA41, Xalatan
  • ATC Code: S01EE01
  • Chemical Formula: C26-H40-O5
  • Molecular Weight: 432.597
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00654 (APRD01065)
  • SMILES: CC(C)OC(=O)CCCC=C/C[C,H]1[C,,H](O)C[C,,H](O)[C,,H]1CC[C,,H](O)CCC1=CC=CC=C1
  • InChl: GGXICVAJURFBLW-CEYXHVGTSA-N
  • PubChem: 5311221
  • IUPAC: propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate

Additional Details

Indication:
Latanoprost is used to reduce elevated intraocular pressure for patients diagnosed with open-angle glaucoma or ocular hypertension. The recommended dosage of Latanoprost is one drop in each affected eye daily, preferably in the evening. Treatment with Latanoprost should not exceed one drop daily, and it is not advisable for patients to use two more prostaglandin analogs concomitantly. A reduction of intraocular pressure is seen roughly 3 to 4 hours after dosing, with the maximum effect being reached by the 12 hour mark.
Pharmacodynamics:
Latanoprost is an isopropyl ester prodrug which is inactive but which becomes active after hydrolysis to the acid from. Latanoprost opthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.
Mode of Action:
Latanoprost is a prostaglandin F2a analogue. Specifically, Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Thought of as a plumbing problem for the eye, Glaucoma is essentially when the drainage system of the eye is clogged. This clogging increases ocular pressure (IOP) and damages the optic nerve, leading to the diagnosis of glaucoma. If patients experience a prolonged period of time with elevated eye pressure they may have significant vision loss as a repercussion.
Metabolism:
Primarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1,2-dinor and 1,2,3,4-tetranor metabolites by fatty acid beta-oxidation.
Toxicity:
Between 5 and 15 percent of patients administered Latanoprost for six months or longer report at least one adverse effect from this drug. Common side effects reported include redness, blurry vision, burning, itching and stinging in the eye. Latanoprost may cause a long term change in the color of eyes, eyelids and eyelashes. These changes occur gradually and may be permanent.
General Reference:
Hara T: [Increased iris pigmentation after use of latanoprost in Japanese brown eyes] Nippon Ganka Gakkai Zasshi. 2001 May;105(5):314-21. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials